Abiraterone acetate is a CYP17 inhibitor suitable for use in combination with prednisone for the treatment of patients with previously transplanted castration-refractory prostate cancer with docetaxel [docetaxel].
White or off-white powder
506.7°C at 760 mmHg
Research reagents, widely used in molecular biology, pharmacology and other scientific research
Warnings and precautions
(1) Mineralocorticoid excess: Patients with a history of cardiovascular disease use ZYTIGA with caution. The safety of ZYTIGA in patients with ejection fraction LVEF < 50% or NYHA class III or IV heart failure has not been determined. Control high blood pressure and correct hypokalemia before treatment. Check blood pressure, serum potassium and fluid retention symptoms at least once a month.
(2) Adrenal insufficiency: Monitor symptoms and signs of adrenal insufficiency. It may be appropriate to increase the corticosteroid dose before, during and after an emergency.
(3) Hepatotoxicity: An increase in liver enzymes has led to drug interruption, dose adjustment and/or termination. Monitor liver function and, if recommended, adjust, discontinue or discontinue ZYTIGA dosing.
(4) Food effects: ZYTIGA must be taken on an empty stomach. When exposed to food with abiraterone acetate abiraterone, the exposure (area under the curve) increased by a factor of 10.
The most common adverse reactions (≥ 5%) are joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flashes, diarrhea, urinary tract infections, cough, high blood pressure, arrhythmia, frequent urination, nocturia, indigestion, And upper respiratory tract infection.